Bone
mineral density, body mass index and cigarette smoking among Iranian women:
implications for prevention.
BMC Musculoskelet Disord. 2005; 6:34 (ISSN:
1471-2474)
Baheiraei A; Pocock NA; Eisman JA; Nguyen ND; Nguyen TV
Bone and Mineral Research Program, Garvan Institute of Medical Research,
St Vincent's Hospital, University of New South Wales, Sydney, Australia.
a.baheiraei@garvan.org.au
Tồn Trữ Tài Liệu Khảo Cứu Y Dược Khoa Của Người Việt
Bs Nguyễn Ðình Nguyên và Ts Nguyễn Văn Tuấn Cùng Các Ðồng Nghiệp với Nghiên Cứu >>>back>>>
Severe pulmonary hypertension: walking through new paths to revisit an old field
A.T. Dinh-Xuan1, M. Humbert2 and R. Naeije3
1 Service de Physiologie-Explorations Fonctionnelles, Centre Hospitalier Universitaire Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris V, Paris, France, 2 Service de Pneumologie, Hôpital Antoine Béclère, Clamart, France, and 3 Dépt des Soins Intensifs, Hôpital Universitaire Erasme, Brussels, Belgium
CORRESPONDENCE: A.T. Dinh-Xuan, Service de Physiologie-Explorations Fonctionnelles, Hôpital Cochin, 27, rue du faubourg Saint-Jacques, 75679, Paris cedex 14, France. Fax: 33 158412345. E-mail: anh-tuan.dinh-xuan@cch.ap-hop-paris.fr
Almost 10 yrs ago, a series of manuscripts on pulmonary hypertension appeared in the European Respiratory Journal 1–9. These in-depth reviews caused a great deal of interest in the readers as they covered various aspects of this unique condition, which causes hypertension in a region of the body in which the artery blood pressure should always remain low, as opposed to its systemic counterpart. Almost 10 yrs later, exciting new stories about the origin, mechanisms, identification and cure of this pulmonary disorder have slowly emerged that are certainly worth telling now.
One of the most dramatic breakthroughs was the recent discovery of the role played by bone morphogenetic protein receptor type II (BMPR-II) gene in the pathophysiology of familial pulmonary hypertension 10. This led to a revival of interest in the use of genetic studies to dissect mechanisms and pathways leading to pulmonary vascular disease 12. However, it soon became clear that the discovery of genes involved in disease would be of little help if the signalling pathways that are perturbed as a result of gene mutation could not be delineated. Following the same pattern, another recent breakthrough, which will certainly shed new light on understanding of pulmonary vascular physiology, was the discovery that the serotonin transporter (5-HTT) could play a pivotal role in the mechanisms leading to pulmonary vascular remodelling and severe pulmonary hypertension 13. The crosstalk between 5-HTT and BMPR-II signalling pathways is yet to be clearly defined 14. Nevertheless, it is probable that these factors are not alone as other crucial players like gelatinase 15 or endothelin 16 are also likely to be involved in this complex and intricate biological puzzle.
Although understanding the cause of severe pulmonary hypertension is crucial, it is certainly not the ultimate target. The main concern remains how to detect the disease in its early development and how to cure patients of this dreadful condition. Fortunately, progress has been made on all fronts of this unique battle, ranging from noninvasive evaluation of pulmonary arterial pressure 17 to medical treatment and surgical procedures.
In this issue of the European Respiratory Journal, a new series of 12 reviews, written by those who are at the forefront of biological and clinical research in pulmonary hypertension, will begin with an article by Humbert and Trembath 18. The present authors hope that this series will be more than simply a sequel to the first series of manuscripts published 10 yrs ago, and are confident that these short reviews will provide insights and generate new ideas for readers when revisiting familiar fields of knowledge through recently discovered paths. Hopefully, this can be as interesting as rereading a favourite old book; re-examining the once overlooked pages and their obscure messages that become all at once obvious in the spotlight of new discoveries.
References
Higenbottam TW, Rodriguez-Roisin R. Highlights on pulmonary hypertension: a commentary. Eur Respir J 1993;6:932–933.[ISI][Medline] [Order article via Infotrieve]
Higenbottam TW, Cremona G. Acute and chronic hypoxic pulmonary hypertension. Eur Respir J 1993;6:1207–1212.[ISI][Medline] [Order article via Infotrieve]
Agustí AGN, Rodriguez-Roisin R. Effect of pulmonary hypertension on gas exchange. Eur Respir J 1993;6:1371–1377.[Abstract]
Naeije R. Medical treatment of pulmonary hypertension in acute lung disease. Eur Respir J 1993;6:1521–1528.[Abstract]
Weitzenblum E, Kessler R, Oswald M, Fraisse P. Medical treatment of pulmonary hypertension in chronic lung disease. Eur Respir J 1994;7:148–152.[Abstract/Free Full Text]
Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995;8:2129–2138.[Abstract/Free Full Text]
Chaouat A, Weitzenblum E, Higenbottam TW. The role of thrombosis in severe pulmonary hypertension. Eur Respir J 1996;9:356–363.[Abstract/Free Full Text]
Kessler R, Chaouat A, Weitzenblum E, et al. Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences. Eur Respir J 1996;9:787–794.[Abstract/Free Full Text]
Kneussl MP, Lang IM, Brenot FP. Medical management of primary pulmonary hypertension. Eur Respir J 1996;9:2401–2409.[Abstract/Free Full Text]
Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737–744.[CrossRef][ISI][Medline] [Order article via Infotrieve]
Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-ß receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81–84.[CrossRef][ISI][Medline] [Order article via Infotrieve]
Newman JH, Wheeler L, Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001;345:319–324.[Abstract/Free Full Text]
Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001;108:1141–1150.[Abstract/Free Full Text]
Rabinovitch M. Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension. J Clin Invest 2001;108:1109–1111.[Free Full Text]
Frisdal E, Gest V, Vieillard-Baron A, et al. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J 2001;18:838–845.[Abstract/Free Full Text]
Takahashi H, Soma S, Muramatsu M, Oka M, Ienaga H, Fukuchi Y. Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery. Eur Respir J 2001;18:5–14.[Abstract/Free Full Text]
Naeije R, Torbicki A. More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur Respir J 1995;8:1445–1449.[Free Full Text]
Humbert M, Trembath RC. Genetics of pulmonary hypertension: from bench to bedside. Eur Respir J 2002;20:741–749.[Abstract/Free Full Text]
Tồn Trữ Tài Liệu Khảo Cứu Y Dược Khoa Của Người Việt
Bs Anh-Tuấn Dinh-Xuân và các đồng nghiệp vơí Nghiên Cứu
>>>back>>>
Tồn Trữ Tài Liệu Khảo Cứu Y Dược Khoa Của Người Việt
Bs Daniel Trương và các đồng nghiệp với Nghiên Cứu:
Cervical dystonia severity scale reliability study
Christopher O’Brien, MD, Allison Brashear, MD, Paul Cullis, MD, Daniel Truong, MD, Eric Molho, MD, Stephen Jenkins, MD, Joanne Wojcieszek, MD, Thomas O’Neil. MD, Stewart Factor, MD, Lauren Seeberger, MD
Colorado Neurological Institute, Englewood, Colorado, USA
Indiana University School of Medicine, Indianapolis, Indiana, USA
Wayne State University School of Medicine, Detroit, Michigan, USA
Fountain Valley, California, USA
Albany Medical College, Albany, New York, USA
Allergan, Inc., Irvine, California, USA
Macomb Hospital, Warren, Michigan, Michigan, USA
Lọan trương lực cơ ở cổ là do bắp thịt cổ co cứng gây tư thế cổ bất bình thường. Phương pháp đo độ trương lực cơ trầm trọng ở cổ (Cervical Dystonia Severety Scale) được thành lập với mục đích giúp đo chính xác kết quả điều trị bệnh lọan trương lực ở cổ cho bệnh nhân. Phương pháp này dùng dụng cụ gắp (protractor) và bản đồ (wall chart) để đo độ ngọeo cổ trầm trọng của đầu từ vị trí thẳng tới 3 vị trí xoay, ngọeo sang một bên hoặc ngọeo đằng trước/đằng sau (rotation, laterocollis, anterocollis/retrocollis), được điểm khỏang cách 5 độ (độ lệch từ 1 tới 5=1; từ 86 tới 90 độ lệnh=18).
Để kiểm chứng độ chính xác (reliability) của phương pháp đo lọan trương lực cơ ở cổ, hiện có 4 trung tâm (2 trung tâm độc lập) đang nghiên cứu 42 bệnh nhân bị nghẹo cổ. Nơi nào cũng dùng cách đo vị trí đầu bằng độ trương lực cơ, 4 lần cho mỗi bệnh nhân, và mỗi bệnh nhân đo 2 lần. Giá trị kappa vào khỏang 0.94 (95% tin tưởng giới hạn ở 0.900-0.972; 95% confidence limit of 0.900-0.972), tức là có độ chính xác tuyệt hảo giữa các chuyên gia khi đo lường. Tóm lại, phương pháp đo trương lực cơ cô? có độ chính xác cao khi so sánh đo lường của các khảo sát viên trong một nhóm hay giữa các nhóm thực hiện.
Reference: Christopher O’Brien, MD, Allison Brashear, MD, Paul Cullis,
MD, Daniel Truong, MD, Eric Molho, MD, Stephen Jenkins, MD, Joanne Wojcieszek,
MD, Thomas O’Neil, MD, Stewart Factor, MD, Lauren Seeberger, MD: Cervical
dystonia severity scale reliability study. Movement Disorders, 16: 1086-1090,
2002.
Correspondence: Daniel Truong, M.D.
The Parkinson’s and Movement Disorders Institute
9940 Talbert Ave #204
Fountain Valley, Ca 92708
Telephone: (714) 378-5662
<www.pmdi.org> <http://www.pmdi.org>
Bs Daniel Trương
>>>back>>>
Tồn Trữ Tài Liệu Khảo Cứu Y Dược Khoa Của Người Việt
Bs Khanh Vinh Quoc Luong, Bs Lan Thi Hoang Nguyen và Bs Dung Ngoc Pham Nguyen với Nghiên Cứu: The Role of Vitamin D in Protecting Type 1 Diabetes Mellitus DIABETES/METABOLISM RESEARCH AND REVIEWS REVIEW ARTICLE Diabetes Metab Res Rev 2005; 21: 338–346.
Published online 26 April 2005 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/dmrr.557
The role of vitamin D in protecting type 1 diabetes mellitus
Khanh vinh quoc Luong1*
Lan Thi Hoang Nguyen1
Dung Ngoc Pham Nguyen1,2
1Vietnamese American Medical Research Foundation, Westminster, California
2Metropolitan State Hospital, Norwalk, California
*Correspondence to: Khanh vinh quoc Luong, 14971 Brookhurst Street, Westminster, CA. 92683, USA. E-mail: Lng2687765@aol.com
Received: 3 March 2004
Revised: 15 July 2004
Accepted: 10 March 2005
Summary
The relationship between autoimmune diabetes or type 1 diabetes mellitus and vitamin D has been reported in the literature. Many factors, environmental and genetic, have been known, as risk factors, to cause both type 1 diabetes and vitamin D deficiency. Vitamin D treatment has improved or prevented type 1 diabetes mellitus in animals and humans. Vitamin D also has been known to protect from autoimmune diseases in animal models. Therefore, it would be interesting to review the role of vitamin D in type 1 diabetes mellitus. Copyright 2005 John Wiley & Sons, Ltd.
Keywords vitamin D; diabetes mellitus; 1,25-dihydroxyvitamin D3
Bs Khanh Vinh Quoc Luong, Bs Lan Thi Hoang Nguyen và Bs Dung Ngoc Pham Nguyen
>>>back>>>
